Deutsche Bank Ag\ Rallybio Corp Transaction History

Deutsche Bank Ag\

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.31 - $8.89 $17,658 - $36,422	-4,097 Reduced 24.92%	12,342 $69,000
Q1 2023 May 15, 2023	BUY	$4.37 - $8.75 $36,271 - $72,625	8,300 Added 101.98%	16,439 $93,000
Q4 2022 Feb 13, 2023	BUY	$4.67 - $14.86 $495 - $1,575	106 Added 1.32%	8,139 $53,000
Q3 2022 Nov 14, 2022	SELL	$7.54 - $14.56 $7,999 - $15,448	-1,061 Reduced 11.67%	8,033 $116,000
Q2 2022 Aug 11, 2022	SELL	$6.26 - $13.65 $3,668 - $7,998	-586 Reduced 6.05%	9,094 $69,000
Q1 2022 May 13, 2022	BUY	$6.91 - $15.04 $36,699 - $79,877	5,311 Added 121.56%	9,680 $68,000
Q4 2021 Feb 11, 2022	BUY	$9.3 - $19.91 $2,139 - $4,579	230 Added 5.56%	4,369 $42,000
Q3 2021 Nov 04, 2021	BUY	$10.83 - $23.4 $44,825 - $96,852	4,139 New	4,139 $73,000

31.9M

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $30.5M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.